Vir Biotechnology (VIR) CFO restructures 5,000 shares via family trust transfer

Rhea-AI Filing Summary

Vir Biotechnology EVP & CFO Jason O'Byrne reported an internal restructuring of 5,000 shares of Common Stock, described as a transfer without consideration for estate planning purposes. The filing shows 2,500 shares moved from his direct holdings and 2,500 shares recorded as indirectly held.

After these transactions, O'Byrne holds 160,115 shares directly and 2,500 shares indirectly through the O'Byrne Family Trust, where he and his spouse serve as trustees. The Form 4 does not reflect any open‑market buying or selling, but rather a non-cash reallocation of ownership.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider O'Byrne Jason

Role EVP & Chief Financial Officer

Type	Security	Shares	Price	Value
Other	Common Stock	2,500	$0.00	--
Other	Common Stock	2,500	$0.00	--

Holdings After Transaction: Common Stock — 160,115 shares (Direct); Common Stock — 2,500 shares (Indirect, See Footnote)

Footnotes (1)

1. Transfer without consideration for estate planning purposes. The shares are held in the name of the O'Byrne Family Trust, of which the Reporting Person and his spouse are Trustees.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Byrne Jason

(Last) (First) (Middle)

C/O VIR BIOTECHNOLOGY, INC.

1800 OWENS STREET, SUITE 900

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2026		J(1)		2,500	D	$0	160,115	D
Common Stock	03/20/2026		J(1)		2,500	A	$0	2,500	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transfer without consideration for estate planning purposes.

2. The shares are held in the name of the O'Byrne Family Trust, of which the Reporting Person and his spouse are Trustees.

Remarks:

	/s/ Vanina de Verneuil, Attorney-In-Fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Vir Biotechnology (VIR) disclose for Jason O'Byrne?

Vir Biotechnology disclosed that EVP & CFO Jason O'Byrne reported an internal restructuring of 5,000 Common Stock shares. The Form 4 characterizes this as an “other” transaction, not a market buy or sell, linked to estate planning and entity-level ownership changes.

Were Vir Biotechnology (VIR) shares bought or sold in the Jason O'Byrne Form 4?

The Form 4 for Jason O'Byrne does not show any open-market purchases or sales. Instead, both entries use code J, indicating other acquisitions or dispositions tied to restructuring, with footnotes describing the move as a transfer without consideration for estate planning purposes.

How many Vir Biotechnology (VIR) shares does Jason O'Byrne hold after the reported transactions?

After the reported restructuring, Jason O'Byrne holds 160,115 Vir Biotechnology shares directly and 2,500 shares indirectly. The indirect position is held through the O'Byrne Family Trust, where he and his spouse serve as trustees, according to the Form 4 ownership details.

What is the role of the O'Byrne Family Trust in the Vir Biotechnology (VIR) filing?

The filing states that 2,500 Vir Biotechnology shares are held in the name of the O'Byrne Family Trust. Jason O'Byrne and his spouse are trustees of this trust, and the transaction is described as a transfer without consideration carried out for estate planning purposes.

What does transaction code J mean in the Vir Biotechnology (VIR) Form 4?

Transaction code J in the Form 4 is labeled as “Other acquisition or disposition.” In this Vir Biotechnology filing, both J-coded entries are further explained by footnotes as a transfer without consideration, related to estate planning and movement of shares involving the O'Byrne Family Trust.

Does the Vir Biotechnology (VIR) Form 4 indicate any cash proceeds for Jason O'Byrne?

The Form 4 notes that the restructuring involved a transfer without consideration, suggesting no cash proceeds to Jason O'Byrne. The reported transactions reclassify how 5,000 shares are held between direct ownership and the O'Byrne Family Trust, rather than reflecting a market trade.